Posted by Michael Wonder on 24 Jul 2018
AbbVie prices new endometriosis drug at $10,000 a year
24 July 2018 - Drugmaker AbbVie priced its new endometriosis drug Orilissa at around $10,000 a year after receiving approval from U.S. regulators for the treatment on Tuesday.
Orilissa was approved by the FDA for the management of moderate to severe pain associated with endometriosis. The company, along with partner Neurocrine Biosciences Inc, released positive Phase III results for the drug for treatment of uterine fibroids.
The company said it will price the drug at $844.87 per month.
